A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies by unknown
Goss et al. J Transl Med  (2016) 14:83 
DOI 10.1186/s12967-016-0836-6
RESEARCH
A phase I study of high-dose 
rosuvastatin with standard dose erlotinib 
in patients with advanced solid malignancies
Glenwood D. Goss1,2,3* , Derek J. Jonker2,3, Scott A. Laurie2,3, Johanne I. Weberpals1,4, Amit M. Oza5, 
Johanna N. Spaans1, Charles la Porte1 and Jim Dimitroulakos1,2,6*
Abstract 
Background: Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical mod-
els across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity 
of escalating doses of rosuvastatin in combination with the standard clinical dose of erlotinib in heavily pretreated 
patients with advanced solid tumours.
Methods: This was a single-center, phase I open-label study to determine the safety and recommended phase 
two dose (RPTD) of rosuvastatin in combination with 150 mg/day standard dose of erlotinib. Using a 3 + 3 study 
design and 28-day cycle, escalating doses of rosuvastatin from 1 to 8 mg/kg/day ×2 weeks (cycle 1) and 3 weeks 
(subsequent cycles) given concurrently with erlotinib were evaluated. In order to expand the experience and to gain 
additional safety and pharmacokinetic data, two expansions cohorts using concurrent or alternating weekly dosing 
regimens at the RPTD were also evaluated.
Results: All 24 patients enrolled were evaluable for toxicity, and 22 for response. The dose-limiting toxicity (DLT) of 
reversible muscle toxicity was seen at the 2 mg/kg/day dose level. Maximal tolerated dose (MTD) was determined to 
be 1 mg/kg/day. Thirty-three percent of patients developed at least 1≥ grade 2 muscle toxicity (rhabdomyolysis: 1/24, 
myalgia: 7/24) resulting in one study-related death. Durable stable disease for more than 170 days was seen in 25 % 
of patients that received concurrent treatment and were evaluable for response (n = 16). Plasma erlotinib levels on 
study were unaffected by the addition of rosuvastatin.
Conclusions: The observed disease stabilization rate of 25 % with combination therapy in this heavily pretreated 
population is encouraging, however, the high levels of muscle toxicities observed limited this combination strategy.
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Background
A large body of experimental and clinical evidence sup-
ports the view that the epidermal growth factor recep-
tor (EGFR) is a relevant target for cancer therapy [1–3]. 
Two small molecule EGFR tyrosine kinase inhibitors 
(EGFR-TKIs; gefitinib and erlotinib) are approved for 
the treatment of advanced non-small cell lung can-
cer (NSCLC) in the first-line setting in patients whose 
tumors harbor an activating EGFR mutation [4, 5]. 
Despite early response rates of 60–80  %, resistance to 
EGFR-TKIs in this population usually develops within 
a year [6–9]. EGFR-TKIs are also approved as second-
line therapy in unselected NSCLC patients who have 
failed chemotherapy, with response rates of 10–12  % 
and improved overall survival of 2 months, from 4.7 
to 6.7  months [10]. In other epithelial derived cancers 
that generally express wild-type EGFR like squamous 
cell carcinomas, breast and prostate cancers, response 
rates to EGFR-TKIs are generally less than 5 % [11–13]. 
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population, novel combination regimens with EGFR-
TKIs are required.
Mevalonate pathway metabolites are critical for the 
function or the appropriate expression/localization of 
receptor tyrosine kinases (RTKs), including EGFR, and 
the effectors of their downstream signaling cascades [14–
16]. The rate-limiting step of the mevalonate pathway 
is the conversion of HMG-CoA to mevalonate, which 
is catalyzed by HMG-CoA reductase [15]. Deregulated 
or elevated activity of HMG-CoA reductase has been 
demonstrated in a variety of different tumours [17, 18]. 
The statin family of drugs are potent inhibitors of HMG-
CoA reductase that are well-tolerated and widely used 
as treatments for hypercholesterolemia at standard daily 
doses of 5–40 mg/day [17] with the most common side 
effects being myalgia, nausea, diarrhea and constipation 
[19]. Importantly, in preclinical studies high-dose statin 
treatment has been shown to directly block tumour cell 
growth, invasion and metastatic potential both in  vitro 
and in vivo [18, 20, 21]. In a phase I study of lovastatin 
monotherapy in patients with solid tumors (n  =  88), 
the MTD was determined to be 25  mg/kg/day based 
on 1-week of consecutive dosing, followed by a 3-week 
break every 28-day cycle [22]. Although roughly 25 times 
the normal upper limit of doses used to treat hypercho-
lesterolemia, this weekly regimen failed to demonstrate 
clinical efficacy as an anticancer therapy [22]. Of impor-
tance to this study, we demonstrated that HMG-CoA 
reductase was a target of retinoid action [23] and that 
retinoid responsive tumour types are particularly sensi-
tive to statin-induced apoptosis that includes acute mye-
loid leukemias, paediatric malignancies and squamous 
cell carcinomas (SCC) [24, 25]. This work led to our 
phase I trial in recurrent SCC (n = 26) using a prolonged 
oral administration of lovastatin that established 7.5 mg/
kg/day ×  21 days in a 28-day cycle as the MTD, with a 
DLT of reversible muscle toxicity [26]. Importantly, in 
this study 23 % of these end-stage patients displayed dis-
ease stabilization lasting greater than 3 months, albeit in 
the absence of any objective responses [26]. With the aim 
to enhance their clinical anticancer efficacy, high-dose 
statins where then evaluated in combination with EGFR-
TKIs, as detailed below.
In preclinical studies, we demonstrated that combina-
tion treatment with lovastatin and EGFR-TKIs at con-
centrations between 1 and 10  μM induced synergistic 
cytotoxicity in SCC, NSCLC and colon cancer cell lines 
[27, 28]. Statin treatment was shown to inhibit ligand 
induced dimerization, autophosphorylation and intracel-
lular trafficking of the EGFR [29]. Based on this encour-
aging preclinical data and given the manageable toxicities 
of high-dose single-agent statin observed in prior phase I 
studies [22, 26], we undertook this current phase I study, 
evaluating escalating doses of rosuvastatin with standard 
dose erlotinib. Erlotinib was chosen based on its safety 
and tolerability profile in phase I–III studies, the most 
common side-effects consisting of rash, fatigue, ano-
rexia and diarrhea [30]. Rosuvastatin was chosen for its 
enhanced bioavailability and activity over lovastatin [31]. 
Further, as a non-CYP3A4 substrate [32], rosuvastatin 
was expected to have a reduced likelihood of drug:drug 
interaction with erlotinib at the elevated doses required 
to achieve relevant anticancer serum levels. The specific 
aims of this phase I study were to define the RPTD, DLTs 
and the pharmacokinetic interaction of rosuvastatin with 
erlotinib when used in combination in the treatment of 
patients with advanced solid tumours.
Methods
Study design and eligibility
This was a single-center, phase I open-label study to 
determine the safety and RPTD of rosuvastatin in com-
bination with the standard clinical dose of erlotinib 
(150  mg/day) in patients with advanced solid tumours. 
This study was approved by Health Canada and the 
Ottawa Hospital Research Ethics Board (2007908-
01H) and described at ClinicalTrials.gov (Identifier: 
NCT00966472). Eight cohorts from 1 to 8  mg/kg/day 
rosuvastatin given concurrently with standard dose 
erlotinb in 28-day cycles were planned. Eligible adult 
patients had a diagnosis of advanced/metastatic (stage 
IIIB/IV) incurable solid malignancies. Patients received 
therapy until evidence of disease progression, the devel-
opment of serious or unmanageable adverse events 
(SAE), or until study withdrawal. Clinically or radio-
logical documented disease and an ECOG performance 
status of 0, 1 or 2 was also required. All study patients 
had adequate hematogical, hepatic and renal func-
tions at baseline. Adequate hematological function was 
defined as hemoglobin  ≥90  g/L, absolute granulocyte 
count ≥1.5 ×  109/L and platelet counts ≥100 ×  109/L. 
Biochemical parameters for hepatic function included; 
total bilirubin  <1.5× the upper limit of normal (ULN) 
and ALT/AST  <1.5× ULN. Adequate renal function 
was defined as a creatinine clearance  >60  ml/min as 
measured by 24  h urine collection. Any anticholesterol 
agents were discontinued at least 7 days prior to starting 
the trial. Other exclusion criteria included known brain 
or leptomeningeal metastases, no prior EGFR inhibitor 
therapy, no known neuromuscular disorders as well as 
known hypersensitivity or allergy to HMG-CoA reduc-
tase inhibitors including rosuvastatin in Asian popula-
tions which were also excluded [33], (US FDA Public 
Health Advisory, 2 March 2005, www.fda.gov).
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Treatment
Erlotinib was provided by Roche Canada and was 
administered orally in tablet form at a standard daily 
dose of 150  mg. This dose was chosen based on its 
established safety and efficacy in pre-treated patients 
with advanced cancer [30]. The starting dose of rosuv-
astatin was 1  mg/kg/day with the dose of rosuvastatin 
increasing in a step-wise manner in escalating doses of 
1  mg/kg/day. The 1  mg/kg/day starting dose (~80  mg/
day) represents the highest tested hypercholesterolemia 
dose for rosuvastatin and was chosen for safety [34]. 
During cycle-1 of the dose escalation, treatment with 
rosuvastin was administered as follows: 1 week off, then 
daily for 2  weeks, then 1  week off. For all subsequent 
cycles, rosuvastatin was given daily for the first 3 weeks 
of each 28-day cycle, a schedule that was successfully 
employed in the previous phase I study of lovastatin 
in SCC patients [26]. Doses were rounded to the near-
est 5 mg since rosuvastatin is available in 5, 10, 20 and 
40  mg tablets (purchased from AstraZeneca, Canada). 
Oral administration of rosuvastatin was once daily if 
daily dose was <80 mg, twice if 81–160 mg, three times 
a day if 161–240  mg and four times a day if  >240  mg 
daily dose. Similar dosing schedules were incorporated 
in previous high dose statin trials [22, 26]. No prophy-
lactic medications were supplied. Standard supportive 
care medications were allowed. Oral supplementation 
of ubiquinone at 60 mg po QID was initiated if patient 
developed grade 3 or 4 muscle toxicity and continued 
until recovery to baseline.
A 3 + 3 dose escalation phase I study design was used, 
with 3 patients planned at each cohort. If no dose-limit-
ing toxicity during the first treatment cycle was observed 
in the first 3 patients, then dose escalation was planned 
for the next cohort of 3 patients. All 3 patients at a given 
dose level needed to complete the first cycle of treatment 
without suffering DLT before new patients were enrolled 
at the next dose level. The lead patient at each new dose 
level completed the first cycle of treatment before other 
patients were enrolled at the same dose level. If 1/3 ini-
tial patients at each dose experienced a DLT, then the 
treatment level was expanded to at least 6 patients. If 
no more than 1 of 6 patients experienced DLT, then 
the next cohort of patients was to be treated at the next 
higher dose level. There was no dose escalations allowed 
within individual patients. If >2 patients at any dose level 
experienced DLT, then that level was considered to have 
exceeded the maximal tolerated dose (MTD), and the 
level immediately preceding that level was designated as 
MTD and RPTD. An expansion cohort was also proposed 
at the RPTD of rosuvastatin to expand experience and to 
gain additional safety and efficacy data of this combina-
tion regimen.
Toxicity
All toxicity grading was according to the NCI com-
mon toxicity criteria version 2 [35]. DLT was defined as 
any first-course,  >grade 3 non-hematological toxicity 
(excluding alopecia or inadequately controlled nausea/
vomiting), grade 4 neutropenia or with fever, grade 4 
thromocytopenia, or dose delay of >2 weeks due to drug-
related toxicity. Patients who recovered from DLT were 
able to continue on study with a dose reduction to the 
next lower dose level at investigator’s discretion.
On study evaluation
Patients had weekly laboratory evaluations for hema-
togical, hepatic and renal functions and biochemical 
changes including creatine and creatine phosphokinase 
(CPK) and fasting total cholesterol, HDL and LDL during 
cycle 1 and at the start of each subsequent cycle. Physical 
examinations occurred at the start of each cycle and radi-
ological tumor evaluations were completed after every 
2 cycles. Tumor response was assessed using response 
evaluation criteria in solid tumors (RECIST) criteria [36].
Treatment duration and follow‑up
All patients received treatment until clinical and/or radi-
ologic progression, unacceptable toxicity, patient refusal 
or if the treating physician felt that continued partici-
pation was no longer in the best interest of the patient. 
In these cases, the patient went off protocol treatment. 
Patients with objective response, disease stabilization, or 
symptomatic improvement were allowed to continue the 
treatment at the investigator’s discretion until evidence 
of disease progression or serious toxicity. Myalgia, myo-
pathy and, rarely rhabdomyolysis may occur in patients 
treated with rosuvastatin at all doses [34] presenting with 
muscle pain or muscle weakness in conjunction with 
increases in creatine kinase (CPK) values to greater than 
10 times the upper limit of normal. For Grade 3 events, 
rosuvastatin treatment will be held until resolution and 
restarted at one lower dose level and for Grade 4 toxici-
ties; the patient will be removed from the protocol. Simi-
lar strategies were employed for other toxicities as well. 
All patients were seen in follow-up 4 weeks after the last 
treatment and were monitored for any on-going adverse 
effects, late adverse effects and death. Institutional 
Research Ethics Board approval was obtained prior to the 
start of this study, and all study subjects provided written 
informed consent. This study was conducted according 
to Good Clinical Practice.
Pharmacokinetic evaluation and analysis
Unlike other statins, rosuvastatin is not a CYP3A4 sub-
strate [33] and was not expected to display drug:drug 
interaction with erlotinib. However, due to the 
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significantly higher doses of statins required to achieve 
anticancer serum levels, we undertook pharmacoki-
netics of this treatment combination. Pharmacokinetic 
analysis of erlotinib serum levels was undertaken at day 
6 (erlotinib alone) and at day 14 (erlotinib and 1 mg/kg/
day rosuvastatin treatments) and rosuvastatin at the day 
14 timepoint of cycle 1 in 6 study patients (Schedule A). 
On day 6 and 14 serum erlotinib levels and day 14 serum 
rosuvastatin levels were determined at 2  h intervals for 
a full 24 h after drug treatments. The analysis of rosuv-
astatin and erlotinib was performed by a validated liquid 
chromatography mass spectrometry/mass spectrom-
etry (LC/MS/MS) method [37, 38]. Protein precipitation 
(plasma: 50/50 acetonitrile/menthol 1:2) was used for 
sample preparation before injecting to HPLC for separa-
tion. Rosuvastatin, erlotinib and internal standard (IS), 
6,7-Dimethyl-2,3-di(2-pyridyl)-quinoxaline (DMDPQ) 
was eluted by HPLC (Accela, Thermo) using a gradient 
mobile phase [0.2 % Formic acid (V:V), and 100 % meth-
anol]. The chromatographic separation was achieved 
at room temperature on a 1.9  μm C18 column (Hyper-
sil Cold; 2.1 ×  50  mm, Thermo) equipped with a 2-cm 
pre-column packed with the same material at 200  μL/
min. Detection was done by tandem Mass spectrometer 
(TSQ Quantum Access MAX, Thermo) with electrospray 
ionization in positive mode. The multiple reaction moni-
toring (MRM) was be used to detect specific precur-
sor ion to product ion transitions for rosuvastatin (m/s 
482.3/258.1), erlotinib (m/s 394.3/336.2), and IS (m/s 
313.2/91.2), respectively. Xcalibur and TSQ Tune master 
software (Thermo) was used as the system controller and 
integrator.
Both rosuvastatin and erlotinib were stable for 24 h at 
4  °C after sample preparation and during 3 freeze-thaw 
cycles. The linear calibration ranges in plasma were from 
0.25 to 200 μg/L for Rosuvastatin and 6.25–3000 μg/L for 
Erlotinib, respectively. The recoveries were above 85  % 
for both drugs at three concentrations. And Intra- and 
inter-day precisions for both drugs were less than 12 %.
Results
Study conduct
Two levels of dose-escalation were attempted. One of 
the last patients enrolled in the second cohort (2 mg/kg/
day rosuvastatin) developed Grade 4 rhabdomyolysis, 
which led to a study related death and established the 
1 mg/kg/day dose of rosuvastatin as the MTD and RPTD 
when used in combination with 150 mg of erlotinib. As a 
result of this unexpected death, the study was amended 
to include a second expansion cohort at the RPTD to 
evaluate the impact of alternating weekly erlotinib and 
rosuvastatin treatment on the safety of this combination 
regimen. As detailed in Fig. 1, four patients were enrolled 
at the first dose (1 mg/kg/day) as the second study patient 
withdrew consent prior to receiving rosuvastatin and 
eight patients were enrolled in the second cohort (2 mg/
kg/day). At the 2  mg/kg/day escalation dose, 8 patients 
were enrolled with the original 3 patients to be expanded 
by another 6 patients due to the development of skin rash 
in the 3 patients that is associated with erlotinib clinical 
activity but stopped at a total of 8 patients due to a study 
related death. An additional 12 patients were accrued to 
the expansion cohorts, with 6 patients enrolled to into 
Schedule A (an expansion of Cohort 1 at 1  mg/kg/day 
rosuvastatin) and 6 patients into Schedule B, which used 
an alternating weekly schedule of rosuvastatin (1 mg/kg/
day) and erlotinib (Fig.  1b). In total, eighteen patients 
were treated concurrently with erlotinib and rosuvastatin 
and six with an alternating weekly schedule of rosuvasta-
tin and erlotinib.
Patient characteristics
Patient characteristics are outlined in Table 1, according 
to the type of combination regimen received (concur-
rent or alternating). There were similar median ages and 
gender ratios between the concurrent treatment group 
(Cohorts 1, 2 and Schedule A) and the alternating treat-
ment group (Schedule B) at 60 vs 54 years and 60 vs 67 % 
male gender, respectively. A variety of tumor types were 
represented in both the concurrent and alternating treat-
ment regimens including NSCLC, which represented 
29  % of all patients evaluated. Patients were gener-
ally heavily pre-treated, with 70  % having undergone at 
least two previous treatment regimens and 80 % having 
received prior radiation therapy.
Response
Twenty-four eligible patients were enrolled on study with 
two patients not evaluable for response due to early study 
withdrawal during the first cycle. In addition to these two 
patients, another five patients did not complete cycle 1 due 
to progressive disease. No objective responses were seen 
employing RECIST criteria [36]. Patients were analyzed 
based on whether they received concurrent treatments 
with these two agents (Cohorts 1 and 2 and Schedule A, 
a total of 16 evaluable patients) or were treated with alter-
nating weekly does of rosuvastatin and erlotinib treat-
ments (Schedule B, 6 evaluable patients). Of particular 
interest, 4/16 evaluable patients treated concurrently 
were on study for greater than 170 days, with 3 patients 
on study for greater than 275 days (Fig. 2a). The tumour 
types of patients displaying durable stable disease were 
2/4 NSCLC patients, 1/2 pancreatic cancer (responsive 
patient; neuroendocrine tumour) and 1/4-genitourinary 
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(GU) cancer patients (vaginal squamous epithelial car-
cinoma) (Fig.  2b). This stable disease is highlighted by 
the Thorax CT scans of one of the NSCLC patients that 
was on study, the pre-treatment scan at-15  days and a 
subsequent scan at 218  days on study are shown (Addi-
tional file 1: Figure S1). Further, of the patients that came 
off study with progressive disease (n  =  19), a subset of 
these patients also displayed prolonged progression free 
survival of greater than 175 days (Fig. 2c) and a waterfall 
plot of patient days on study also highlight the subset of 
patients with stable disease (Fig. 2d).
Toxicities
All 24-study patients were evaluable for toxicity. Adverse 
events were documented for each treatment regimen. 
The ≥Grade 2 toxicities are listed in Table 2 and are con-
sistent with those previously observed with single agent 
erlotinib or rosuvastatin. Anorexia (15/24 patients) and 
rash (7/24), common toxicities observed with erlotinib 
treatment, were observed in all cohorts. Muscle toxici-
ties (grade ≥2) known to be associated with statin ther-
apy, included fatigue (18/24), muscle weakness (10/24) 
and myalgia (7/24) and were common across all cohorts. 
Fig. 1 Phase I trial outline. a Schematic of the patient cohorts including patient numbers and treatment regimens evaluated in this study. b Treat-
ment schedules employed in this Phase I study
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The rate of muscle pathologies was more pronounced at 
the 2 mg/kg/day dose, indicating the potential of a dose 
effect. At this higher dose, a single patient out of 8 evalu-
able patients developed rhabdomyolysis, which resulted 
in a study related death. This patient had baseline and 
day 6 (erlotinib only) serum levels in the normal range 
for alanine transaminase (ALT), albumin and CPK meas-
ures of hepatic, renal and muscle health, respectively. 
However at day 28 (erlotinib and rosuvastatin treatment), 
significant increases in all three-serum markers were 
observed, particularly with CPK levels which increased 
from 60 U/L to over 2000 U/L, suggesting rosuvastatin-
induced muscle damage (Additional file 2: Figure S2). In 
the 2 mg/kg/day dose (Cohort 2), 4 out of the 8 patients 
enrolled had elevated CPK levels during rosuvastatin 
treatments compared with only 1 out of 16 patients at the 
1 mg/kg/day dose. Surprisingly, treatment with rosuvas-
tatin did not result in significant changes in serum cho-
lesterol, LDL or HDL levels, even in patients on study for 
greater than 170 days (Additional file 3: Figure S3). Given 
the elevated CPK levels and the DLT of muscle toxicity 
observed at the 2/mg/kg/day dose level, 1 mg/kg/day was 
established as the RPTD.
Pharmacokinetic analyses
Pharmacokinetic analysis of erlotinib serum levels was 
performed at day 6 (erlotinib alone) and at day 14 (erlo-
tinib and 1  mg/kg/day rosuvastatin treatments) in the 
6 patients enrolled in Schedule A (Fig.  1). The erlotinib 
levels at each time-point for each patient are depicted 
in Fig.  3a. In the five evaluable patients who received 
both erlotinib and rosuvastatin, the area under the curve 
(AUC) for erlotinib did not differ significantly between 
day 6 and day 14 (Fig.  3b). Furthermore, the maximum 
concentration observed for each patient (Cmax) and 
the time to obtain the Cmax (Tmax) were also similar 
in both treatments (Table  3). The half-life of erlotinib 
was also consistent and was unaffected by the addition 
Table 1 Patient characteristics
Concurrent Cohorts 1 and 2/Schedule A Alternating Schedule B All patients
Number of patients 18 6 24
Age (years)
 Median/range 60/43–70 54/44–63 58/43–70
Gender
 Male 11 (60 %) 4 (67 %) 15 (63 %)
 Female 7 (40 %) 2 (33 %) 9 (37 %)
Ethnicity
 Caucasian 23 (96 %)
 Other 1 (4 %)
Primary tumour
 NSCLC 5 2 7
 Esophageal 4 4
 Pancreas 2 1 3
 GU 4 2 6
 Colon 2 2
 Breast 1 1
 Unknown 1 1
Number Frequency Percent
Previous treatment regimens
 1 7 29.2
 2 8 33.3
 3 6 25.0
 >3 3 12.5
Reason Off protocol
 Progressive disease 19 79.2
 Adverse event 1 4.2
 Patient withdrawal 2 8.3
 Other 2 8.3
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of rosuvastatin. Pharmacokinetic analysis of rosuvasta-
tin serum levels was also performed at day 14 (erlotinib 
and 1  mg/kg/day rosuvastatin treatments; single dose) 
in the five evaluable patients who received both erlo-
tinib and rosuvastatin, the area under the curve (AUC) 
for rosuvastatin is presented (Fig.  3c). As expected the 
nM serum concentrations are elevated compared to the 
hypercholesterolemia dose (approximately 1/2 to 1/4 the 
dose employed in this study) [39]. Patient variability has 
been consistently demonstrated irrespective of dose [39] 
and is observed in this study as well, however, due to the 
treatment schedule employed a comparison in the same 
patients of rosuvastatin serum levels with or without 
erlotinib treatment were not evaluated.
Discussion
In our phase I study of combination therapy with high-
dose rosuvastatin and standard dose erlotinib, concur-
rent treatment resulted in stable disease lasting >170 days 
in 25 % of these heavily pretreated patients, albeit in the 
absence of objective responses. Despite choosing a drug 
combination that minimized the chance of drug:drug 
Fig. 2 Patient responses on study. a Days on study for each evaluable patient segregated into concurrent treatments (Cohorts 1 and 2-dose 
escalation and Schedule A) and the alternating weekly schedule (Schedule B). b Days on study based on tumour type in the concurrent treatments. 
c Kaplan-Meir curve evaluating progression free survival in all evaluable patients. d Waterfall plot of the number of days on study of evaluable 
patients in this study
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interactions, this combination regimen showed signifi-
cant toxicities. The rate of myalgia in our study (34  %), 
was substantially higher than the rate observed with 
therapeutic doses of statin therapy used in the treatment 
of hyperlipidemia (1–5  %) [40]. Two escalating levels of 
rosuvastatin were performed, based on a standard 3 + 3 
study design, with the second dose of rosuvastatin result-
ing in a study-related death.
The dose-limiting muscle toxicities associated with 
the combined administration of high-dose rosuvastatin 
and erlotnib was unexpected, and had not been previ-
ously reported in phase I studies with single agent high-
dose statin treatment in solid tumours [22]. Notably, in 
our earlier phase I study of single agent lovastatin in SCC 
patients with advanced cancers of the head and neck or 
cervix, of the 24 patients enrolled, 5 patients experienced 
reversible dose-limiting muscle toxicities, only 2 of which 
were greater than grade 2 in severity [26]. The low μM 
concentration range (0.8–3.9) and intra-patient variabil-
ity observed following 150  mg treatment with erlotinib 
is in keeping with previously published reports [41]. Our 
pharmacokinetic data suggest a lack of drug:drug interac-
tion in patients treated concurrently with standard dose 
erlotinib and high-dose rosuvastatin, and cannot explain 
the excessive toxicity observed with this combination 
regimen. Given the absence of an observed drug:drug 
interaction, our results support the continued use of low 
dose rosuvastatin in the treatment of hypercholester-
olemia in patients on erlotinib.
In unselected patients, high dose single agent statin 
treatments have not demonstrated clinical activity. In 
our phase I study in SCC patients, a tumour type that 
showed significant statin-induced apoptosis in  vitro, 
disease stabilization of greater than 3 months in 23 % of 
patients was observed [26]. In this study, in a non-selected 
patient population that included a single SCC patient, 
similar rates but more pronounced disease stabilization 
(greater than 6  months for 4/16 patients in the concur-
rent treatment regimens) was observed. This included 
2/4 NSCLC, 1/2 pancreatic cancer (responder; neuroen-
docrine tumour) and a single SCC (vaginal carcinoma) 
patient. In a recent study conducted by Han et al. [42], the 
hypercholesterolemia dose of simvastatin was employed 
in a daily regimen with the standard dose of gefitinib in 
NSCLC patients. In particular, SCC patients displayed 
higher response rates and longer PFS compared to gefi-
tinib alone. This study was based on our work that showed 
in vitro synergy of this approach as well as the ability of 
statins to inhibit EGFR function [27, 29, 42, 43]. Taken 
together, these results suggest that high-dose statin ther-
apy in combination with EGFR-TKIs may be beneficial in 
a subgroup of patients with advanced solid cancers.
Although contributing to our understanding of the 
therapeutic potential of high-dose statins as part of com-
bination anti-cancer therapy, our study has limitations. 
Due to limited tumor availability, EGFR mutation testing 
was only possible on 8/24 study patients (all wild-type, 
including the SCC patient with stable disease). As such, 
EGFR mutation positivity cannot be discounted as a pos-
sible reason for the prolonged stable disease observed 
in the two NSCLC patients (mutation status unknown), 
although this response is not typical of the tumour 
regressions observed in erlotinib treated EGFR activating 
mutation patients [7]. Our study established 1 mg/kg/day 
Table 2 Adverse events
a Study related death
Patients 1 mg/kg/day 2 mg/kg/day Alternating All n = 24
Cohort 1/Schedule A  
n = 10
Cohort 2  
n = 8
Schedule B  
n = 6
Completed 1st cycle 7/10 (70 %) 5/8 (63 %) 5/6 (83 %) 17/24 (71 %)
Toxicities grade (%) 2 3 4 2 3 4 2 3 4
Rash 1 4 2 29.2
Diarrhea 3 1 1 20.8
Anorexia 5 2 4 4 62.5
Weight loss 1 1 2 16.7
Anxiety 1 4.2
Nausia 3 1 16.7
Vomiting 4 16.7
Fatigue 4 4 5 1 2 2 75.0
Muscle weakness 1 1 6 1 1 41.7
Myalgia 2 3 1 1 29.2
Rhabdomyolysis 1 4.2a
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Fig. 3 Pharmacokinetic analysis of Schedule A patients. a Serum erlotinib levels were determined for these patients at day 6 (erlotinib alone, left 
panel) and at day 14 (erlotinib + rosuvastatin treatments) every 2 h following drug administration for 24 h. b For the 5 evaluable patients (14–18), 
area under the curve (AUC) values showed no statistical difference between the two treatments with respect to serum erlotinib exposure. P value 
determined by T test. c Serum rosuvastatin levels were determined for these patients at day 14 (erlotinib +1 mg/mg/day rosuvastatin treatments) 
every 2 h following drug administration for 24 h
Table 3 Pharmacokinetic analysis of erlotinib in Schedule A patients
13 14 15 16 17 18
Erlotinib alone (day 6)
 AUC (μM) 23.45 29.68 45.44 46.19 13.87 50.14
 Cmax (μM) 2.17 1.83 2.73 2.97 0.86 3.42
 Tmax (h) 6 6 8 8 8 8
 t 1/2 (h) 7.1 25.7 18.1 15.1 15.4 9.4
Erlotinib (+rosuvastatin) (day 14)
 AUC (μM) off study 34.32 62.74 59.51 21.22 24.81
 Cmax (μM) off study 1.96 3.95 3.90 1.19 1.57
 Tmax (h) off study 8 6 10 10 8
 t1/2 (h) off study 24.3 14.5 12.8 12.8 13.3
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(for 3/4 weeks) as the RPTD of rosuvastatin in combina-
tion with standard daily dosing of 150  mg/day erlotinib 
with a significant durable stable disease observed in a 
subgroup of our heavily pre-treated patients. Given the 
significant dose limiting muscle toxicities associated with 
their combined use, alternate treatment strategies that 
can mimic the anti-cancer effects of statins without the 
associated toxicities may represent a more refined thera-
peutic approach in the treatment of advanced cancer.
Conclusions
Our laboratory in preclinical models has demonstrated 
synergistic cytotoxicity with high-dose statins and EGFR-
TKIs across a number of tumour types. In this phase I 
study, we employed escalating doses of rosuvastatin in 
combination with erlotinib in patients with advanced 
solid tumours. Importantly, no drug:drug interactions 
were demonstrated between these two agents. The 
observed disease stabilization rate of 25  % with combi-
nation therapy in this heavily pretreated population is 
encouraging, however, the high levels of muscle toxicities 
observed limited this combination strategy.
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